2018
The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review
Khetrapal P, Lee M, Tan W, Dong L, de Winter P, Feber A, Kelly J. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 66: 56-63. PMID: 29684744, DOI: 10.1016/j.ctrv.2018.03.007.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsBladder cancerBlood-based biomarkersValidation cohortTumor cellsDiagnostic value of circulating tumor cellsCirculating tumor cell biomarkerDetection of bladder cancerSystematic reviewCell-free DNAIndependent validation cohortCirculating nucleic acidsSolid cancersAUC/ROC valueUrinary biomarkersMedian numberDiagnostic valueCancerBiomarker sensitivityBiomarkersNucleic acidsBladderSystematic searchCohortAUC/ROC
2017
Abstract 5702: A targeted re-sequencing assay for molecular profiling of somatic mutations from plasma cell-free dna (cfdna) for bladder cancers
Dong L, Khetrapal P, Rodney S, Tan W, Rezaee S, Winter P, Kelly J, Feber A. Abstract 5702: A targeted re-sequencing assay for molecular profiling of somatic mutations from plasma cell-free dna (cfdna) for bladder cancers. Cancer Research 2017, 77: 5702-5702. DOI: 10.1158/1538-7445.am2017-5702.Peer-Reviewed Original ResearchPlasma cell-free DNAProfiles of somatic mutationsCell-free DNAMetastatic BCBladder cancerNext generation sequencingSomatic mutationsAmerican Association for Cancer Research annual meetingsCfDNA samplesMolecular profilingStratify patient managementResponse to chemotherapyMonitoring treatment responseAbstract Bladder cancerDetect somatic mutationsTechnical duplicatesAllele frequenciesIllumina MiSeq sequencing platformNext generation sequencing workflowMutational burdenTumor DNAImprove patient outcomesMiSeq sequencing platformTreatment responseTumor heterogeneity